Compare Orchid Chemicals with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs PANACEA BIOTECH - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD PANACEA BIOTECH ORCHID PHARMA LTD/
PANACEA BIOTECH
 
P/E (TTM) x -0.5 10.5 - View Chart
P/BV x 0.1 2.2 5.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
PANACEA BIOTECH
Mar-19
ORCHID PHARMA LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs194354 54.9%   
Low Rs35138 25.3%   
Sales per share (Unadj.) Rs276.574.6 370.8%  
Earnings per share (Unadj.) Rs-79.26.7 -1,185.9%  
Cash flow per share (Unadj.) Rs-43.515.5 -280.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.957.2 94.3%  
Shares outstanding (eoy) m70.4561.25 115.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.3 12.6%   
Avg P/E ratio x-1.436.8 -3.9%  
P/CF ratio (eoy) x-2.615.9 -16.6%  
Price / Book Value ratio x2.14.3 49.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,06715,061 53.6%   
No. of employees `0002.82.3 121.0%   
Total wages/salary Rs m2,5271,471 171.8%   
Avg. sales/employee Rs Th6,956.11,973.6 352.4%   
Avg. wages/employee Rs Th902.5635.6 142.0%   
Avg. net profit/employee Rs Th-1,993.0176.8 -1,127.3%   
INCOME DATA
Net Sales Rs m19,4774,567 426.5%  
Other income Rs m40745 908.9%   
Total revenues Rs m19,8844,612 431.2%   
Gross profit Rs m1,1032,030 54.3%  
Depreciation Rs m2,519540 466.5%   
Interest Rs m5,2271,048 498.6%   
Profit before tax Rs m-6,236486 -1,282.6%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-12577 -162.4%   
Profit after tax Rs m-5,580409 -1,364.0%  
Gross profit margin %5.744.4 12.7%  
Effective tax rate %2.015.9 12.7%   
Net profit margin %-28.79.0 -319.8%  
BALANCE SHEET DATA
Current assets Rs m11,0142,415 456.2%   
Current liabilities Rs m32,0609,077 353.2%   
Net working cap to sales %-108.1-145.9 74.1%  
Current ratio x0.30.3 129.2%  
Inventory Days Days9565 145.8%  
Debtors Days Days3471 47.3%  
Net fixed assets Rs m29,4408,333 353.3%   
Share capital Rs m70561 1,149.3%   
"Free" reserves Rs m2,0433,443 59.3%   
Net worth Rs m3,8003,504 108.4%   
Long term debt Rs m9,018461 1,955.3%   
Total assets Rs m46,51013,755 338.1%  
Interest coverage x-0.21.5 -13.2%   
Debt to equity ratio x2.40.1 1,803.1%  
Sales to assets ratio x0.40.3 126.1%   
Return on assets %-0.810.6 -7.2%  
Return on equity %-146.911.7 -1,257.8%  
Return on capital %-3.738.7 -9.7%  
Exports to sales %37.920.9 181.4%   
Imports to sales %22.68.1 277.8%   
Exports (fob) Rs m7,378954 773.4%   
Imports (cif) Rs m4,406372 1,184.7%   
Fx inflow Rs m7,5131,203 624.5%   
Fx outflow Rs m5,649467 1,210.5%   
Net fx Rs m1,865736 253.2%   
CASH FLOW
From Operations Rs m1,6821,049 160.3%  
From Investments Rs m-9,860-54 18,430.7%  
From Financial Activity Rs m6,644-1,011 -656.9%  
Net Cashflow Rs m-1,535-20 7,791.9%  

Share Holding

Indian Promoters % 32.3 74.5 43.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.6 766.7%  
FIIs % 3.3 1.3 253.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 23.6 234.3%  
Shareholders   84,811 10,259 826.7%  
Pledged promoter(s) holding % 54.9 35.1 156.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS